Abstract 1865P
Background
This study aimed to determine how the chemotherapy process can lead to a change in self-esteem in elderly patients with early-stage breast cancer according to personality type.
Methods
The research was completed as a pilot study between 2019-2022. Female patients aged 65 and over who were planned for adjuvant treatment were included in the study. Personality type and self-esteem were determined in all patients before and after adjuvant chemotherapy. Bortner Rating Scale was used to determine personality type, and Rosenberg Self-Esteem Scale was used to determine self-confidence. Paired t-test was performed for recurrent variables in pre-treatment and post-treatment measures. Multivariate logistic (binary) regression analysis was performed to determine the independent factors affecting low self-esteem from the study variables with the model created as a result of correlation and univariate analysis. Statistical analysis was performed using the SPSS v19 program and a p value of <0.05 was considered statistically significant.
Results
A total of 69 Her2-negative elderly female patients were included in this pilot study. The mean age of the patients was 68 years (65-72). 54% had radical mastectomy. 69% received paclitaxel for 12 weeks, 21% received 6x DC, and 10% received 3x CEF followed by 3x docetaxel for adjuvant setting. 56% of them had personality type A. Before treatment, 62% had high self-esteem and this was significantly higher in type A personality than in type B (84% vs 48%, respectively; p=0.037). While the rate of high self-esteem decreased in type A personality after treatment (p=0.009), there was no change in type B personality (p=0.379). It was determined that type A personality structure was independent affecting low self-esteem after treatment (OR 5.37 95%CI 1.489-9.396; p=0.006).
Conclusions
In this study, it was concluded that elderly women with type A personality structure may be more sensitive and may have low self-esteem after the treatment is completed. It was concluded that the personality type should be guided by the patient's treatment compliance, need for psychosocial support, and coping methods after the completion of the treatment, supported by the physician.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Ethics committee approval could not be obtained because it was a pilot study. In the follow-up research, the results of the pilot study will be declared and consent will be obtained.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
2018P - Novel nomogram based on the expression of DLL3 and PD-L1 for predicting the prognosis of small cell lung cancer patients
Presenter: Jun Zhao
Session: Poster session 05
2019P - Analysis of lung immune prognostic index (LIPI) score in a small cell lung cancer carcinoma (SCLC) cohort, supporting its prognostic use and investigating its predictive potential
Presenter: Mónica Esteban García
Session: Poster session 05
2020P - Circulating micro RNAs (cmiRNAs) as treatment outcome predictors in extensive small cell lung cancer (eSCLC) patients (pts) receiving atezolizumab plus carboplatin and etoposide (ACE): CATS/ML43257 study
Presenter: Giulia Pasello
Session: Poster session 05
2021P - Cell-free (cf) DNA as predictive biomarker (B) of treatment outcome in extensive small cell lung cancer (eSCLC) patients (pts) receiving atezolizumab, carboplatin and etoposide (ACE): CATS/ML43257 study
Presenter: Giulia Pasello
Session: Poster session 05
2022P - ALBA project: Prognostic impact of laterality in small cell lung cancer
Presenter: Lorenza Landi
Session: Poster session 05
2024P - Supportive measures to control myelosuppression and costs for patients with SCLC with lurbinectedin, CAV or topotecan with or without trilaciclib: A review on the basis of clinical trials
Presenter: Manuel Dómine
Session: Poster session 05
2025P - Stratified control study of neuroendocrine differentiation and potential clinicopathologic markers
Presenter: Li Liu
Session: Poster session 05
2026P - Small cell lung cancer (SCLC) in the KBP-2020-CPHG cohort and comparison with 2000 and 2010
Presenter: Lionel Falchero
Session: Poster session 05
2027P - Immune checkpoint inhibitors in the treatment of small cell lung cancer: A systematic review and meta-analysis
Presenter: Patsy Lee
Session: Poster session 05